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Abstract 
HIV gp120 is specifically cleaved at a single site in the V, loop between Arg315 and Ala316 by thrombin. Previous observations by others have 
indicated that binding to CD4 enhances the rate of Vg loop cleavage, and that this cleavage is a prerequisite for HIV infection. Other observations 
also suggest hat the cleavage site is in a type II B-turn centered at Pro313 -Gly314. However, our docking experiments indicate that this conformation 
cannot dock to thrombin and other trypsin-like serine proteases. Thus, based on the thrombin-bound conformation of peptide substrates, we propose 
that CD4 binding, at a site remote from the V, loop, induces and stabilizes a trans to cis isomerization of the highly conserved residue Pro”‘, and 
that this conformational shift is a prerequisite for cleavage by a ‘thrombin-like’ cellular protease and subsequent infection. 
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1. Introduction 
The human immunodeficiency virus infects cells fol- 
lowing the binding of the viral envelope glycoprotein 
gp120 to the cell surface receptor CD4 [1,2]. However, 
the binding and infective processes can be separated 
[3,4]. Antibodies to the principal neutralizing determi- 
nant in the V, loop prevent infection, but do not inhibit 
binding to CD4 [5-71. It has also been suggested that 
proteolytic cleavage of this loop, probably by a trypsin- 
like serine protease at the cell surface, is a prerequisite 
to viral infection [8], and that cleavage is enhanced by 
sCD4 binding and inhibited by neutralizing antibodies 
to the V, loop [9]. 
Gp120 is cleaved specifically at a single site in the V3 
loop between R315 and A316 by thrombin [lo]. Thrombin 
cleavage of gp120 is enhanced by sCD4 binding and is 
abrogated by transient exposure to nonionic detergent 
[9,11], underlining the importance of substrate confor- 
mation. Hattori and coworkers reported that trypstatin, 
a Kunitz-type proteinase inhibitor of coagulation factor 
Xa, prevented infection [8]. A strong homology exists 
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between the active site inhibitory region of trypstatin and 
the highly conserved region of the gp120 V, loop [8], and 
certain structural features are conserved despite hyper- 
variability in the loop. The GPGR sequence from resi- 
dues 312-315 is found in 85-90% of HIV isolates [12]. 
Additionally, Gotoh et al. have shown that factor Xa 
from chick embryo is a critical determinant in para- 
myxovirus activation in chick embryos [13,14]. Muta- 
tions at G312, G314 or R315 produce non-infectious virions, 
thus highlighting the importance of this region, although 
the P313 to A313 mutation did not prevent infection [15]. 
Secondary structure analysis [ 121, solution NMR [16], 
and X-ray crystallographic studies [17] suggest hat this 
sequence, immediately preceding the thrombin cleavage 
site, forms a type II /?-turn, with Pro313 at the i + 1 posi- 
tion, and with the adjacent segments forming antiparallel 
p-strands [12,16]. 
Thrombin exhibits substantial secondary structure 
speci6city for a B-sheet-turn-sheet motif, with the reverse 
turn appositely orienting substrates for binding to 
thrombin [18-201. In this work, we have compared the 
predicted secondary structure for the consensus equence 
. ..RKSIHI---GPGR*AFY [12] and other high probabil- 
ity sequences for the principal neutralizing determinant 
(PND) region of the gp120 V, loop with the thrombin- 
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bound conformation of fibrinopeptide [21,22], and offer 
a hypothesis and working model for examination of the 
CD4 induced conformational changes involved in the 
requisite proteolysis of the gp120 V, loop prior to fusion. 
Our results suggest hat the enhancement of the cleavage 
rate observed upon CD4 binding to gp120 results from 
CDCinduced translcis isomerization and stabilization of 
the cis Pro313 configuration. In the /?-turn i + 2 position, 
the cis form of Pro313 would be compatible with a type 
VI reverse turn at the tip of the V3 loop; this conforma- 
tional shift is required to permit cleavage by thrombin, 
factor Xa or a related thrombin-like cellular protease. 
2. Materials and methods 
Models for the bound structures of the V, loop peptides from gp120 
were constructed using the Insight11 modeling program (Biosym Tech- 
nologies Inc.), using BPTI and the bound structure of fibrinopeptide 
A within the thrombin binding site [1%22] as a template. Thrombin 
coordinates were obtained from the crystal structure of the hirudin- 
thrombin complex [18]. Factor Xa coordinates were those of a recently 
solved structure at 2.2 A resolution [23]. Criteria for construction of the 
models included the requirements that: (i) the Arg residue side chain 
at the Pl cleavage site was fixed within its Sl subsite, (ii) the 9,9 angles 
for the gp120 substrates were similar to the P2 to Pl 459 angles for 
BPTI, (G) key hydrogen bonds and hydrophobic interactionscritical 
for substrate bindine in the thrombin 121.221 and factor Xa active sites 
were maintained, aid (iv) the insertions’ and deletions in the various 
HIV gp120 isolates could be accommodated. Following manual con- 
struction of various models, the structures were energy minimized, and 
examined to ensure that 9,9 dihedral angles were within allowed re- 
gions. 
3. Results 
Construction of a type II turn with Pro at the i + 1 
position, and placement within the thrombin active site 
is shown in Fig. 1, from which it can be seen that the Pro 
residue exhibits substantial clashing interactions with 
thrombin HisS7, and with the insertion loop Tyr@‘A and 
TrpaD residues. The active site of factor Xa exhibits 
similar collisions, also shown in Fig. 1. Attempts to reo- 
rient the positioning of the peptide to remove these unfa- 
vorable interactions, while maintaining the type II /?-turn 
with Pro in the i + 1 position, were uniformly unsuccess- 
ful. Although secondary structure analysis [12], NMR- 
based conformational analysis [ 161, and X-ray crystallo- 
graphic analysis of a V3 loop peptide antigen with an 
HIV-l neutralizing antibody [ 171 would suggest hat the 
gp120 peptide should exhibit a type II p-turn centered at 
Pro313 and Gly314, it is impossible to dock this conforma- 
tion in a productive mode within either the thrombin or 
factor Xa active site regions. 
Following our previous work with fibrinopeptide A 
[20], we have used the Pz to P’ residues of the fibrinopep- 
tide-thrombin crystal structure [21] as a template for 
setting the @,Q, angles of the P313 to R315 residues, while 
using the cis-Pro Type VI turn in the REI protein [24] as 
a template for the turn. This then places the P313 residue 
in a cis configuration in the i + 2 position of a type VI 
turn. This turn motif then permits a favorable interaction 
of the Ile3” residue with the thrombin hydrophobic clus- 
ter, a secondary binding interaction that has been shown 
to contribute greatly to the conformational specificity of 
thrombin cleavage [19,20,25-271. The overlay of our pro- 
posed gp120 consensus equence conformation with the 
thrombin active site is shown in Fig. 2, while Fig. 3 shows 
the proposed gp120 conformation within the factor Xa 
binding site, again showing very reasonable docking. An 
analogous proposed gp120 conformation, with an Arg311 
insertion in the sequence (the most common insertion 
[ 121) can also be readily accommodated within this basic 
structural motif, with the hydrocarbon chain moiety of 
the R side chain in contact with the thrombin hydropho- 
bic cluster, and the guanidinium group making a salt 
bridge with the thrombin G1u19’ side chain carboxyl 
group (not shown). 
In the proposed gp120 conformations, the Pro313 to 
Arg315 segment is juxtaposed with the thrombin segment 
Se?14-G1J16, forming an antiparallel B-pleated sheet. 
The Pro313 carbonyl oxygen and the Arg3” amide are 
hydrogen-bonded to the Gly216 amide and the Se?14 car- 
Fig. 1. Stereo-diagram showing docking of the gp120 V, loop primary consensus equence with Pro”’ in the i + 1 turn position (-) within the 
thrombin (-) and factor Xa (.....) binding sites. Note the collision of the gp120 residues with those of thrombin and factor Xa, making it impossible 
to productively dock this gp120 model structure within the active site of either enzyme in this conformation. 
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Fig. 2. Stereo-overlay of the gp120 V, loop primary consensus equence with cLr Pro”’ in the i + 2 turn position (-) within the thrombin bmding site 
site (-). Note the positioning of the Ile residue within the hydrophobic luster formed by residues Tyr@‘A and Trp”D, within the thrombin binding 
site. 
bony1 oxygen, respectively, with N.. .O separations of 
2-3 A and angles of 140-160”. These hydrogen bonds 
are commonly observed with the serine proteases and 
their substrates and inhibitors. 
4. Discussion 
Notwithstanding a particularly high variability in the 
external envelope protein gp120, analysis of 245 different 
HIV-l isolates of the PND in the V, loop has shown a 
greater than 80% conservation among 9 out of 14 central 
positions [ 121. This conservation may be due to a require- 
ment to maintain an essential p-strand-turn-strand struc- 
tural motif. The G-P-G-R segment, which is part of the 
consensus sequence . ..RKSIHI---GPGR*AFY... (with 
insertions of Q and R being most common at the dashed 
positions and * indicating the thrombin cleavage site) has 
been predicted to adopt a type II /3-turn in the crown of 
the V, loop [12,16,17,28]. However, with the aid of com- 
puter-assisted molecular modeling, we have determined 
that this conformer can not realistically and productively 
bind in either the deep and narrow thrombin cleft or even 
in the relatively more exposed factor Xa active site (Fig. 
l), and that a conformational shift must occur prior to 
proteolytic cleavage. Thus, we propose that binding of 
gp120 to CD4 at a site remote from the V3 loop induces 
a conformational shift in the V3 loop, which either stabi- 
lizes a cis-proline configuration or enhances the rate of 
proline tram-cis isomerization. Energy calculations sug- 
gest a dG” on the order of 1 to 2 kcal/mol for trans and 
cis proline [29] and an activation barrier of 13 kcal/mol 
(compared with 20 kcal/mol at other peptide bonds) [30]. 
The presence of Gly residues preceding and following 
Pro313 would further stabilize the cis Pro configuration 
[31]. This would favor a frameshift of the reverse turn 
from the presumably favored type II B-turn incorporat- 
ing a truns-proline in the i + 1 position to a type VI turn 
[32] with a cis-proline in the i + 2 site as shown in Fig. 
4. Precedence for this type of isomerism has been ob- 
served by X-ray crystallography for Gly42-Pro43 of cal- 
bindin D,, [33]. This CD4 induced shift would provide 
Fig. 3. Stereo-diagram of the gp120 V3 loop primary consensus equence with cis Pro313 in the i + 2 turn position (-) docked within the factor 
Xa binding site (-). The factor Xa binding cleft, unimpeded by the 60A-D insertion loop, permits binding of the model structure with even greater 
ease. 
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a mechanism for presentation of the V, loop as a compe- 
tent ‘trypsin-like’ substrate to a cellular protease for acti- 
vation for subsequent membrane fusion. 
Although there is a high degree of conservation of the 
GPGR sequence among viral isolates, the residues flank- 
ing this region are hypervariable. In particular, the resi- 
due immediately N-terminal to the conserved region is 
most commonly either Arg (in SF-2, NL4-3 and IIIB 
which are T cell trophic isolates) or Ile (in BaL and 
SF1 62 which are monocyte-macrophage trophic isolates) 
[34]. To examine the role of the sequence variability at 
this site, we docked the two consensus equences within 
the active sites of thrombin and factor Xa. It can be seen 
in Figs. 2 and 3 that the gp120 primary sequence incor- 
porating the type VI turn can be readily accommodated 
in either the thrombin or factor Xa active sites. By com- 
parison with the FPA bound structure [21,22], the turn 
region in the gp120 sequence is more deeply buried in the 
narrow active site of the enzyme. In MT trophic viral 
isolates the consensus residue in the i position of the turn 
is Ile. This residue occupies a site analogous to Leu’ in 
the FPA bound structure. Strong hydrophobic interac- 
tions exist between the Ile side chain and the characteris- 
tic thrombin insertion loop around Tyr60A-Pro60B- 
Pro60C-Trp60D. In factor Xa, the hydrophobic pocket 
formed by TyP9, Phe’74 and Trp215 is unhindered by the 
60A-D insertion loop found in thrombin, thus providing 
more flexible accommodation of the Ile side chain. The 
gp120 conformation proposed for the thrombin active 
site can be docked into factor Xa without any difficulty 
(Fig. 3), and the more open hydrophobic pocket in factor 
Xa allows further adjustment of orientation to provide 
a better fit. The presence of large hydrophobic residues 
in the P3-P4 pockets of thrombin substrates is quite 
common [25]. In contrast, the conserved residue at this 
position is Arg in the T cell trophic viruses (IIIB, SF2) 
[34]. However, this non-conservative replacement can be 
readily accommodated and has precedence for occupy- 
ing this site within thrombin-susceptible sequences [25]. 
The hydrophobic portion of the Arg side chain traverses 
the hydrophobic pocket created by the thrombin inser- 
tion loop and the Arg guanidinium group is within 3.5 
A of the abnormally acidic (by comparison with trypsin) 
G1u19* (residue 192 in factor Xa is Gln). The extended 
Pro3r3 to Arg315 region of the main chain is juxtaposed 
with the thrombin segment Se?14-Gly216 in an antiparal- 
lel, slightly twisted manner; the Pro3130 and the Arg315N 
form favorable hydrogen bonds with the Gly216N and 
Se?140, respectively, forming characteristic interactions 
between thrombin and its substrates and inhibitors. Fur- 
ther details of the interaction between the proposed con- 
sensus sequences and thrombin are shown in Fig. 3. 
Extensive efforts to dock the GPGR turn with Pro313 at 
the i + 1 position with Arg315 positioned in the Sl subsite 
and the scissile amide appositely oriented for interaction 
with Ser19’, proved to be unsuccessful with both throm- 
Fig. 4. Scheme showing the frame-shift moving the Pro313 from a tram 
configuration in the i + 1 position of a type IIB-turn to a cis configura- 
tion in the i + 2 position of a type VI /?-turn 
bin and factor Xa (Fig. l), principally due to the incom- 
patible positioning of the amino-terminal residues (31 l- 
313) deeply within the active site, and causing major 
steric clashes with the thrombin insertion loop (Fig. 1). 
In factor Xa, Pro313 is abutting Tyrw in addition to con- 
straints on the entrance of the amino-terminal to the 
active site. 
The binding of CD4 to HIV-l virions and to the sur- 
face of HIV-l infected cells induces conformational 
changes in the viral envelope that are believed to prime 
the fusogenic activity of gp41. We have suggested a 
working hypothesis for the initial CD4 induced confor- 
mational changes involved in the proteolysis of the 
gp120 V, loop, which is apparently a requisite step in the 
infective process. Although there is a particularly high 
variability in the external envelope protein gp120, analy- 
sis of 245 different HIV-l isolates of the PND in the V3 
loops has shown greater than 80% conservation among 
9 out of 14 central positions [12]. This conservation may 
be due to a requirement to maintain an essential 
/I-strand-turn-strand structural motif. Additionally, 
point mutations at G312, G314 or R315 produce non-infec- 
tious virions [15]. 
In summary, we propose that upon binding to CD4, 
a conformational shift of the Gly312-Pro313 bond from 
tram to cis is either induced or stabilized. Stabilization 
of this conformation might be effected by the interaction 
of conserved acidic residues (particularly G~L?~, in the 
CDR-3 like region of CD4) with a region of N-terminal 
basic residues in the V, loop [35]. This shift would favor 
the proline residue occupying the i + 2 position of a type 
VI /I-turn [32]. Importantly, this hypothesis is consistent 
with the relative unimportance of mutagenesis of Pro313 
to Ala313 [13], in that a type II B turn with Gly312 in the 
i + 1 and Ala313 in the i + 2 position would also be ex- 
pected to be a competent hrombin-like proteolytic sub- 
strate. Alternatively, the type VI turn could be main- 
tained in the P313A variant, as recently observed for a 
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carbonic anhydrase II variant [36]. We suggest hat this 
shift is essential for V, loop cleavage by thrombin, factor 
Xa, or related proteases. Furthermore, this CD4 induced 
conformational shift would provide the virus with a tim- 
ing mechanism which would prevent premature prote- 
olytic cleavage and exposure of gp41 fusion domains 
[37]. Model studies with conformationally constrained 
peptides may be used to evaluate the mechanistic aspects 
of this hypothesis. 
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